CD-34 Immunohistochemistry at Lahore PCR Lab

CD-34 Immunohistochemistry at Lahore PCR Lab

CD-34 Immunohistochemistry (IHC) is a highly specialized pathology test performed at Lahore PCR Lab in Lahore, Pakistan. This diagnostic technique utilizes specific monoclonal antibodies to detect the presence and distribution of the CD34 antigen within tissue samples. CD34 is a 110-kDa transmembrane phosphoglycoprotein primarily expressed on the surface of hematopoietic progenitor cells, vascular endothelial cells, and certain sub-populations of mesenchymal cells, such as interstitial dendritic cells. In the clinical setting, CD34 IHC serves as an indispensable tool for pathologists and oncologists, aiding in the classification of acute leukemias, the characterization of vascular tumors, and the differentiation of various spindle cell neoplasms. By applying this advanced immunohistochemical assay to formalin-fixed paraffin-embedded (FFPE) tissue specimens, Lahore PCR Lab provides clinicians with critical diagnostic, prognostic, and therapeutic insights, ensuring highly personalized patient care.

The clinical utility of CD34 IHC spans multiple medical specialties, including hematopathology, dermatopathology, and surgical oncology. Because CD34 is a marker of immature cells and vascular endothelium, its presence or absence helps resolve complex diagnostic dilemmas. For instance, in bone marrow pathology, CD34 staining allows for the precise quantification of myeloblasts, which is a cornerstone in diagnosing and risk-stratifying myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In soft tissue pathology, the test is crucial for distinguishing between histologically similar but clinically distinct tumors, such as dermatofibrosarcoma protuberans (DFSP) and benign dermatofibroma. By choosing Lahore PCR Lab, patients and referring physicians benefit from state-of-the-art laboratory technology, stringent quality control protocols, and expert interpretation by highly qualified consultant pathologists.

Clinical Procedure: What to Expect

Patient Preparation

Because CD34 Immunohistochemistry is a laboratory analysis performed on tissue samples, there is no direct preparation required for the IHC staining process itself. However, patients must prepare for the primary biopsy or tissue harvesting procedure. The specific preparation instructions depend entirely on the type of biopsy being performed:

• Bone Marrow Biopsy: Patients should discuss their medical history with their physician, particularly regarding bleeding disorders or the use of anticoagulant medications like aspirin, clopidogrel, or warfarin. Fasting may be required if conscious sedation is planned.
• Skin or Soft Tissue Biopsy: Local anesthetic is typically administered, and patients should report any known allergies to anesthetics, antiseptics, or latex. No fasting is generally required for minor outpatient skin biopsies.
• Surgical Excision: For larger tumor resections under general anesthesia, patients must follow standard pre-operative fasting guidelines (usually nothing by mouth for 8 hours prior to the procedure) and complete all pre-operative laboratory clearances.
• Medication Management: Always inform the clinical team of all prescription medications, over-the-counter drugs, and herbal supplements currently being taken, as some may need to be temporarily paused to minimize bleeding risks.

During the Procedure

The laboratory phase of CD34 Immunohistochemistry at Lahore PCR Lab involves a series of highly standardized steps executed by experienced histotechnologists:

• Specimen Reception and Fixation: Once the biopsy specimen is received, it undergoes fixation in 10% neutral buffered formalin to preserve cellular morphology and prevent tissue autolysis.
• Tissue Processing and Embedding: The tissue is processed, dehydrated through graded alcohols, cleared in xylene, and embedded in paraffin wax to create a tissue block.
• Microtomy: Ultra-thin sections of approximately 3 to 4 micrometers are cut using a high-precision microtome and mounted onto positively charged glass slides to ensure tissue adhesion.
• Deparaffinization and Rehydration: The slides are heated and treated with xylene and graded alcohols to remove the paraffin wax and rehydrate the tissue.
• Antigen Retrieval: Heat-Induced Epitope Retrieval (HIER) is performed in a specialized buffer solution to unmask the CD34 glycoprotein epitopes that may have been cross-linked during formalin fixation.
• Antibody Incubation: After blocking endogenous peroxidase activity, the tissue is incubated with a highly specific primary anti-CD34 monoclonal antibody (such as clone QBEnd/10). A secondary detection system conjugated with horseradish peroxidase (HRP) is then applied.
• Visualization and Counterstaining: Diaminobenzidine (DAB) chromogen is added, producing a highly visible brown precipitate at the site of CD34 expression. The slides are counterstained with hematoxylin to visualize cell nuclei, cleared, and coverslipped.
• Pathologist Review: A consultant pathologist at Lahore PCR Lab examines the stained slides under a high-resolution light microscope to evaluate the staining pattern, intensity, and localization.

When is a CD-34 Immunohistochemistry Performed?

Evaluation of Hematopoietic Neoplasms and Acute Leukemias

Physicians frequently request CD34 IHC when evaluating patients presenting with symptoms of hematological malignancies, such as unexplained fatigue, persistent fever, recurrent infections, and easy bruising or bleeding. In the bone marrow, CD34 is a marker of immature hematopoietic stem and progenitor cells. Pathologists use CD34 staining to identify and quantify myeloblasts and lymphoblasts. This is critical for distinguishing acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)—which typically show a high percentage of CD34-positive blasts—from reactive bone marrow states or mature hematological neoplasms.

Diagnosis and Classification of Vascular Tumors

Vascular neoplasms, ranging from benign hemangiomas to highly aggressive angiosarcomas, often present diagnostic challenges due to their varied histological appearances. Since CD34 is naturally expressed by vascular endothelial cells, CD34 IHC is routinely ordered to confirm the endothelial origin of a tumor. This test helps clinicians diagnose conditions like Kaposi sarcoma, epithelioid hemangioendothelioma, and angiosarcoma. It assists in mapping the microvessel density within tumors, which can serve as an indicator of tumor angiogenesis and metastatic potential.

Differential Diagnosis of Spindle Cell Lesions

Spindle cell tumors can arise in various anatomical locations and present with non-specific symptoms such as localized pain or a palpable mass. Distinguishing between different types of spindle cell neoplasms is vital because their clinical management and prognoses differ significantly. CD34 IHC is a key component of the diagnostic antibody panel used to differentiate solitary fibrous tumors (which are characteristically CD34 positive) from other spindle cell mimics, such as synovial sarcoma, leiomyosarcoma, and malignant peripheral nerve sheath tumors (MPNST), which are typically CD34 negative.

Assessment of Dermatofibrosarcoma Protuberans (DFSP)

Dermatofibrosarcoma protuberans is a rare, locally aggressive cutaneous sarcoma that often presents as a slow-growing, painless plaque or nodule on the skin. Clinically and histologically, DFSP can closely resemble benign dermatofibroma (fibrous histiocytoma). To prevent misdiagnosis and ensure appropriate surgical margins, dermatologists and oncologists rely on CD34 IHC. DFSP exhibits strong, diffuse, and continuous CD34 positivity throughout the lesion, whereas dermatofibromas are typically negative or show only focal, superficial staining.

Monitoring Myelodysplastic Syndromes (MDS)

Myelodysplastic syndromes represent a group of clonal bone marrow disorders characterized by ineffective hematopoiesis and cytopenias. Patients often present with severe anemia, fatigue, and recurrent infections. CD34 IHC is performed on bone marrow trephine biopsies to monitor the proportion and distribution of progenitor cells (blasts). An increase in CD34-positive blasts over time or their abnormal localization (abnormal localization of immature precursors, or ALIP) is a critical prognostic indicator that signals a high risk of transformation into acute myeloid leukemia.

What Does a CD-34 Immunohistochemistry Detect?

CD-34 Immunohistochemistry at Lahore PCR Lab is designed to detect the presence, intensity, and distribution of the CD34 glycoprotein within tissue sections. Clinically, this assay detects:

• Normal vascular endothelial cells lining blood vessels.
• Normal hematopoietic stem and progenitor cells in bone marrow.
• Diffuse, strong membranous and cytoplasmic expression in Solitary Fibrous Tumors (SFT).
• Continuous, diffuse CD34 positivity in Dermatofibrosarcoma Protuberans (DFSP).
• Variable CD34 expression in Gastrointestinal Stromal Tumors (GIST), aiding in their identification alongside CD117.
• Elevated myeloblast counts in Acute Myeloid Leukemia (AML).
• Increased lymphoblast populations in B-cell Acute Lymphoblastic Leukemia (B-ALL).
• Abnormal localization of immature precursors (ALIP) in Myelodysplastic Syndromes (MDS).
• Strong endothelial staining in Kaposi Sarcoma lesions.
• Diffuse positivity in Epithelioid Hemangioendothelioma.
• Marked CD34 expression in Spindle Cell Lipomas.
• Intratumoral microvessel density (MVD) to evaluate tumor angiogenesis.
• Positive staining in Pleomorphic Hyalinizing Angiectatic Tumors (PHAT).
• Positive expression in Myofibroblastomas.
• Absence of CD34 staining in benign Dermatofibromas (distinguishing them from DFSP).
• Negative staining in Synovial Sarcomas (aiding in differential spindle cell diagnosis).
• Negative staining in Leiomyosarcomas.
• Negative expression in Malignant Peripheral Nerve Sheath Tumors (MPNST).
• Negative staining in Schwannomas (except for focal, non-specific staining).
• Loss of CD34 expression in dedifferentiated variants of vascular or spindle cell sarcomas.
• Normal adventitial cells surrounding larger blood vessels.
• CD34-positive stromal cells in normal breast tissue and salivary glands.
• Endothelial differentiation in poorly differentiated metastatic carcinomas.
• Positive expression in Endovascular Papillary Angioendothelioma (Dabska tumor).

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely and accurate diagnostic reporting is crucial for managing complex oncological and hematological conditions. The turnaround time for CD34 Immunohistochemistry typically ranges from 3 to 5 working days. This timeframe ensures that the tissue specimen undergoes meticulous processing, high-quality staining, and comprehensive microscopic evaluation by our consultant pathologists. To enhance patient convenience, Lahore PCR Lab provides secure digital access to diagnostic reports. Patients and referring physicians can easily view, download, and print reports through our official online portal or receive them via registered email and SMS alerts. This seamless digital reporting system facilitates prompt clinical decision-making and ensures that treatment planning can proceed without unnecessary delays.

CD-34 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Bone Marrow Myeloblasts	Occasional scattered positive cells (<5% of total cellularity)	Increased CD34+ blasts (>20% indicating Acute Leukemia; elevated levels in MDS)
Vascular Endothelium	Strong, continuous membranous staining in normal vessels	Disorganized, proliferative staining in angiosarcoma or Kaposi sarcoma
Spindle Cell Neoplasms (DFSP vs. DF)	Negative in dermal dendritic cells (except normal adventitial cells)	Strong, diffuse CD34 positivity in Dermatofibrosarcoma Protuberans (DFSP)
Solitary Fibrous Tumor (SFT)	Negative in normal soft tissue stroma	Diffuse, strong cytoplasmic and membranous CD34 positivity
Gastrointestinal Stromal Tumor (GIST)	Negative in normal muscularis propria	Positive CD34 staining (typically co-expressed with CD117 and DOG1)
Schwannoma vs. Neurofibroma	Negative or focal weak staining	Diffuse CD34 positivity in the stromal component of neurofibromas
Tumor Angiogenesis	Normal vascular density appropriate for the tissue type	High microvessel density (MVD) indicating active tumor neovascularization

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CD-34 Immunohistochemistry?

• Experienced Healthcare Professionals: Our team includes highly qualified consultant pathologists and histotechnologists specializing in immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to international standards of quality control and assurance in histopathology.
• Professional Reporting: We provide detailed, structured diagnostic reports with clear pathological interpretations to guide clinical decisions.
• Modern Diagnostic Approach: Our laboratory utilizes advanced automated staining platforms and high-specificity monoclonal antibodies.
• Comfortable Environment: We maintain clean, modern, and safe facilities for all patients and clinical procedures.
• Convenient Location: Located centrally in Lahore, Pakistan, our laboratory is easily accessible for patients and sample drop-offs.
• Commitment to Accurate Diagnosis: We are dedicated to delivering precise, reproducible, and evidence-based diagnostic results.